This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Teva Pharmaceuticals, Israel.
Reference
Smolen L, et al. 10-Year Cost-Effectiveness Analyses of Fremanezumab as Preventive Treatment in Chronic and Episodic Migraine. 24th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PND21, 18 May 2019. Available from: URL: https://www.ispor.org/conferences-education/conferences/upcoming-conferences/ispor-2019/program/posters/detail/intl2019-1479
Rights and permissions
About this article
Cite this article
Fremanezumab cost effective for migraine prevention in the US. PharmacoEcon Outcomes News 830, 15 (2019). https://doi.org/10.1007/s40274-019-5966-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5966-7